Advertisement
Screener

Bausch Health Companies Inc. (BHC) Payments to Noncontrolling Interests

2.8 / 5 stars · 68/120 Roast Me

Bausch Health Companies Inc. Payments to Noncontrolling Interests

Bausch Health Companies Inc. (BHC) reported Payments to Noncontrolling Interests of $18.00 million for the 12-month period ending 2017-12-31, per its 8-K filed 2018-08-10.

Discontinued › Cash Flow › Other Cash Flow Items

us-gaap:PaymentsToMinorityShareholders · last filed 2018-08-10

  • Bausch Health Companies Inc. payments to noncontrolling interests for the quarter ending 2014-06-30 was $0.00.
  • Bausch Health Companies Inc. payments to noncontrolling interests for the quarter ending 2014-03-31 was $3.30M.
  • Bausch Health Companies Inc. payments to noncontrolling interests for the quarter ending 2013-12-31 was -$1.00K, a 100.03% decline year-over-year.
  • Bausch Health Companies Inc. payments to noncontrolling interests for the quarter ending 2013-09-30 was $2.10M.
  • Bausch Health Companies Inc. payments to noncontrolling interests for fiscal 2014 was $8.00M, a 280.95% increase from fiscal 2013.
  • Bausch Health Companies Inc. payments to noncontrolling interests for fiscal 2013 was $2.10M, a 47.50% decline from fiscal 2012.
  • Bausch Health Companies Inc. payments to noncontrolling interests for fiscal 2012 was $4.00M.
  • Bausch Health Companies Inc. payments to noncontrolling interests for fiscal 2011 was $0.00.
Period endPayments to Noncontrolling Interests 3 monthPayments to Noncontrolling Interests 6 monthPayments to Noncontrolling Interests 9 monthPayments to Noncontrolling Interests 12 monthPayments to Noncontrolling Interests 12 month as first filed
2017-12-31$18.00M
8-K · filed 2018-08-10
2016-12-31$9.00M
8-K · filed 2018-08-10
2015-12-31$9.00M
8-K · filed 2018-08-10
$8.30M
10-K · filed 2016-04-29
2014-12-31$8.00M
10-K · filed 2017-03-01
$8.20M
10-K · filed 2015-02-25
2014-06-30$0.00
10-Q · filed 2014-08-01
$3.30M
10-Q · filed 2014-08-01
$3.30M
derived: sum of 3 quarters · filed 2016-04-29
$5.40M
derived: sum of 4 quarters · filed 2016-04-29
2014-03-31$3.30M
10-Q · filed 2014-05-09
$3.30M
derived: sum of 2 quarters · filed 2016-04-29
$5.40M
derived: sum of 3 quarters · filed 2016-04-29
$5.40M
derived: sum of 4 quarters · filed 2016-04-29
2013-12-31-$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-04-29
$2.10M
derived: sum of 2 quarters · filed 2016-04-29
$2.10M
derived: sum of 3 quarters · filed 2016-04-29
$2.10M
10-K · filed 2016-04-29
$2.10M
10-K · filed 2014-02-28
2013-09-30$2.10M
10-Q · filed 2013-11-01
$2.10M
derived: sum of 2 quarters · filed 2014-08-01
$2.10M
10-Q · filed 2013-11-01
$6.10M
derived: sum of 4 quarters · filed 2015-02-25
2013-06-30$0.00
10-Q · filed 2014-08-01
$0.00
10-Q · filed 2014-08-01
$4.00M
derived: sum of 3 quarters · filed 2015-02-25
$4.00M
derived: sum of 4 quarters · filed 2015-02-25
2013-03-31$0.00
10-Q · filed 2014-05-09
$4.00M
derived: sum of 2 quarters · filed 2015-02-25
$4.00M
derived: sum of 3 quarters · filed 2015-02-25
2012-12-31$4.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25
$4.00M
derived: sum of 2 quarters · filed 2015-02-25
$4.00M
10-K · filed 2015-02-25
$0.00
10-K · filed 2014-02-28
2012-09-30$0.00
10-Q · filed 2013-11-01
$0.00
10-Q · filed 2013-11-01
2011-12-31-$28.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28
$0.00
derived: sum of 2 quarters · filed 2014-02-28
$0.00
10-K · filed 2014-02-28
$52.50M
10-K · filed 2012-02-29
2011-09-30$28.52M
10-Q · filed 2012-11-05
$28.52M
10-Q · filed 2012-11-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
Generate Biomedicines, Inc. (GENB)United States$2.052B
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
UroGen Pharma Ltd. (URGN)$2.015B-18.42